Veterinary Society of
Surgical Oncology

General Considerations

  • histologic types: leiomyosarcoma, FSA, undifferentiated sarcoma, liposarcoma, OSA, CSA, myxosarcoma, rhabdomyosarcoma, and fibrous histiocytoma
  • clinical signs: inappetence, abdominal distension, polydipsia, lethargy, vomiting, weight loss, and weakness
  • abdominal mass frequently detected with abdominal palpation and survey abdominal radiographs
  • treatment: splenectomy
  • prognosis is guarded to poor with overall MST 10 weeks
  • MST 1 month for dogs with evidence of metastatic disease at surgery
  • MST 9 months for dogs with no evidence of metastatic disease at surgery
  • Splenic Nodular Hyperplasia

    General Considerations

  • splenic nodular hyperplasia can be classified according to type and proportion of cellular components:
  • lymphoid
  • hematopoietic
  • plasmocytic
  • fibrohistiocytic
  • mixed
  • Nodular Fibrohistiocytic Hyperplasia

  • nodular fibrohistiocytic hyperplasia may represent a transitional form between nodule and malignant neoplasia (i.e., malignant fibrous histiocytoma or generalized histiocytic sarcoma)
  • nodular fibrohistiocytic proliferation in canine spleen characterized by a mixed population of spindle cells in varying proportions with hematopoietic elements, plasma cells, and lymphocytes
  • MST 5.0-5.5 months, with 12-month survival rate 48%
  • 44% of deaths directly attributable to splenic disease
  • poor prognostic factors include low lymphoid-to-fibrohistiocytic ratio and high mitotic index
  • SPLENIC SARCOMA

    Mitotic Index

    Survival

    0-9 cells per 10 high power fields

    12-month survival rate 40%

    > 9 cells per 10 high power fields

    MST 1 month

       
    Back to top